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Abstract
Heat shock proteins have been implicated as endogenous activators for dendritic cells (DCs). Chronic expression of heat
shock protein gp96 on cell surfaces induces significant DC activations and systemic lupus erythematosus (SLE)-like
phenotypes in mice. However, its potential as a therapeutic target against SLE remains to be evaluated. In this work, we
conducted chemical approach to determine whether SLE-like phenotypes can be compromised by controlling surface
translocation of gp96. From screening of chemical library, we identified a compound that binds and suppresses surface
presentation of gp96 by facilitating its oligomerization and retrograde transport to endoplasmic reticulum. In vivo
administration of this compound reduced maturation of DCs, populations of antigen presenting cells, and activated B and T
cells. The chemical treatment also alleviated the SLE-associated symptoms such as glomerulonephritis, proteinuria, and
accumulation of anti-nuclear and –DNA antibodies in the SLE model mice resulting from chronic surface exposure of gp96.
These results suggest that surface translocation of gp96 can be chemically controlled and gp96 as a potential therapeutic
target to treat autoimmune disease like SLE.
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Introduction
SLE is a systemic autoimmune disease characterized by
abnormalities in dendritic cell (DCs), autoreactive T cells and B
cells [1],[2]. DCs are important in regulating both immunity and
tolerance and have been implicated in the pathogenesis of SLE
[1]. DCs induce activation of naı ¨ve T cells and stimulate B cell
growth and differentiation. Therefore, lupus-associated DCs
producing altered signals and amplifying autoreactive specificities
in T cells, which, in turn, provide help to autoreactive B cells,
inducing an increase in autoantibody production. Glomerulone-
phritis is induced when DNA specific autoantibodies form
complexes in kidney glomerulus [3],[4]. As disease progresses,
mesangial proliferation, endocapilliary proliferation, vascular
collapse and immune complex accumulation in kidney result in
glomerulonephritis and eventual renal failure [3],[4]. SLE is
treated by immunosuppresants and cytostatic agents, with
extensive use of corticoids when disease is stabilized, but these
treatments have numerous side effects [5].
Gp96 is the endoplasmic reticulum (ER)-resident chaperone
protein belonging to the HSP90 family [6]. The continuous
recycling of escaped ER resident proteins such as gp96, GRP78/
Bip, protein disulfide isomerase (PDI), and calreticulin is mediated
by retrograde transport form Golgi to ER through COPI-coated
vesicles [7]–[10]. ER localization of these proteins is regulated
through their C-terminal KDEL sequence. KDEL sequence is
recognized by the KDEL receptor ERD2 [11], which is mainly
localized to the cis-Golgi [7],[12]. Binding of KDEL proteins to
ERD2 leads to its oligomerization [13] and stimulates its rapid
transport out of cis-Golgi [14],[15]. Oligomerization seems to be a
hallmark of constitutively cycling proteins of the early secretory
pathway, as ERGIC-53 is a stable hexamer [16] and the KDEL
receptor oligomerizes upon binding to its ligands [13]. gp96 also
exists as a homodimer or higher-order oligomer [17]–[19],
although it is not known whether dimer or higher-order oligomer
is responsible for ERD2 binding. The ERD2-gp96 complex
returns to the ER where it dissociates, thus freeing ERD2 for
further cycling of transport.
In addition to the intracellular chaperone function, gp96 has
been implicated in innate and adaptive immunity [20],[21] and its
cell surface exposure is associated with its immunological activities
such as the activation or maturation of dendritic cells (DCs) [22]–
[24]. Direct interaction between gp96 and DCs via CD91 and
TLR2/4 [25]–[27] induces DC maturation, resulting in proin-
flammatory cytokine secretion and MHC class I and II
upregulation [27],[28]. Transgenic mice chronically expressing
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spontaneous systemic lupus erythematosus (SLE)-like autoimmune
phenotypes [29]. Gp96 is increased in synovial fluid from the joints
of human rheumatoid arthritis patients and the expression of gp96
shows a correlation with inflammation and synovial lining
thickness, further supporting the pathological association of gp96
with autoimmune diseases [30].
AIMP1/p43 (ARS-interacting multi-functional protein 1, also
known as p43) is a protein involved in diverse physiological
processes [31]. Recently, we found that AIMP1 holds gp96 in ER,
preventing its extracellular translocation [32]. For this reason,
AIMP1-deficient mice contain cells with increased surface levels of
gp96, thereby displaying the phenotypes similar to those of
gp96tm transgenic mice [32]. Although all of these previous
studies demonstrated the importance of the ER retention of gp96
to prevent aberrant autoimmune responses, it is not yet
determined whether SLE-like phenotypes resulting from chronic
exposure of gp96 can be compromised by suppressing its surface
translocation. To address this question, we first screened chemical
library to identify a compound that can bind and blocks surface
localization of gp96. After determining the mode of action of the
selected compound upon binding to gp96, we evaluated its in vivo
effect on various phenotypes that are associated with SLE
symptoms using the transgenic mice displaying SLE-like pheno-
types resulting from the chronic surface presentation of gp96.
Results
Screening and Identification of GPM1 as a gp96-Binding
Chemical
Since AIMP1 interacts with gp96 and regulates its ER
localization, preventing cell surface localization [32], we hypoth-
esize that small molecule, having similar activity like AIMP1, can
suppress cell surface localization of gp96 and aberrant autoim-
mune responses although small molecule may compete with
AIMP1 for gp96 binding. For this, we set up modified ELISA
assay method using recombinant AIMP1 and gp96 proteins. The
screening assay was designed to select the compounds that block
the interaction of gp96 with AIMP1 as described in Methods. In
the chemical screening, we chose 6,482 representative chemicals
with different pharmacophore representing 150,000 chemicals
deposited in Korea Chemical Bank (http://www.chembank.org/).
Each of the tested compounds gave different inhibitory effect on
the interaction of the two proteins (Fig. 1A), and we have selected
12 compounds that inhibited the interaction more than 95% of the
control at 0.1mM (Table S1). These 12 compounds had no effect
on the interaction between lysyl-tRNA synthetase (KRS) and
superoxide dismutase 1 (SOD1) [33] indicating the specificity of
compounds. We obtained 1251 additional derivative compounds
from the 12 initial hits and tested them again for the activities
against the gp96-AIMP1 interaction. Among them, 77 compounds
showed negative effect while 1174 compounds gave no effect
(Table S1). The chemicals that would block the interaction of gp96
and AIMP1 are expected to either enhance or suppress the surface
localization of gp96 depending on their binding sites. If chemicals
bind to AIMP1 side, they are expected to enhance the surface
localization of gp96 since it would release gp96 from its
intracellular anchor, AIMP1. But if chemicals bind to gp96 side,
they may suppress the surface translocation of gp96 by interfering
with the subsequent processes for the molecular trafficking of gp96
to the plasma membrane. We thus examined the effects of the 77
compounds on the surface expression of gp96 by flow cytometry as
described. Out of 77 compounds, 8 reduced gp96 positive cells to
below 10% whereas 12 compounds increased gp96 positive cells to
more than 20% and the rest 57 compounds gave the effects within
the range between them (Fig. 1B and Table S1). Among the 8
selected compounds, four were discarded for the following
experiments due to their cellular toxicity (data not shown). In
the next step, we subjected the remaining 4 compounds to the
single dose toxicity test (single i.p. injection, 500mg/kg, 1 week)
using mice. Among them, [(S)-methyl 2-(4,6-dimethoxypyrimi-
dine-2-yloxy)-3-methylbutanoate] (designated as GPM1, Fig. 1C
upper), showed no toxicity (data not shown) and gave high score in
leadlikeness rule [34]. Among other 3 compounds, one gave severe
toxicity to mice and the other two showed low lead-likeness score
(data not shown). Based on these results, we finally chose GPM1
for further experiments. Among the total screened compounds, 2-
(4,6-dimethoxypyrimidin-2-yloxy)-3-phenylpropanoic acid showed
only 4% inhibition on the interaction of gp96 and AIMP1 despite
it shares dimethoxypyrimidine ring with GPM1. We thus selected
it as a control (NC1) (Fig. 1C lower).
We compared the dose-dependent effect of GPM1 and NC1 on
the interaction of gp96 and AIMP1. GPM1 showed 50%
inhibition at around 30nM whereas NC1 gave no effect on the
binding of the two proteins (Fig. 1D). We monitored the binding
kinetics of GPM1 to gp96 or AIMP1 by surface plasmon
resonance (SPR) using BIAcore 3000. GPM1 showed the binding
to gp96 with KD of 87.9nM (Fig. 1E and F), but no apparent
binding to AIMP1 (data not shown). We also determined whether
GPM1 can bind to protein disulfide isomerase (PDI) and GRP78/
Bip that are also an ER-resident KDEL protein like gp96. GPM1
showed extremely weak binding to PDI and GRP78/Bip
compared to gp96 (KD=249 mM and 11.9 mM, respectively)
(Fig. S1A and S1B). To further define the GPM1-binding region of
gp96, we introduced point mutations at L707, V706, V712, L713,
F714, Y731 and M738 that are located within AIMP1-binding
region of gp96 [32] and monitored how the mutations at these
sites would affect the binding of GPM1 to gp96 using SPR
method. All the mutants retained the normal ATPase activity of
gp96 (Fig. S2), suggesting that the mutations did not affect their
native conformation. However, GPM1 showed significantly
decreased affinity to the mutants except for V706A/L707A
mutant, suggesting the importance of the C-terminal dimerization
domain of gp96 for the binding to GPM1.
Suppression of Cell Surface gp96 by GPM1 through
Increased ER Retention
First, we tested the effect of GPM1 on the surface localization of
gp96. We isolated splenocytes from C57BL/6 mice, treated with
vehicle, GPM1, or NC1 (10mM, 24h), and monitored the surface
levels of gp96 by flow cytometry. The surface gp96 levels in
GPM1-treated splenocytes were lower compared to those of the
vehicle- or NC1-treated cells (Fig. 2A). We also determined
whether GPM1 can affect the cell surface level of GRP78/Bip,
PDI, and calreticulin that are also an ER-resident KDEL protein
like gp96. GPM1 had no effect on the populations of the surface
GRP78/Bip, PDI, and calreticulin positive cells while it reduced
gp96-positive cell population, suggesting the specificity of GPM1
for gp96 (Fig. 2B). Next, we examined the action mechanism of
GPM1 for suppression of cell surface gp96. Since GPM1 has no
effect on the cellular protein level of gp96, GPM1 is expected to
have two action points. The first possibility is that GPM1 directly
enhances the endocytosis of cell surface gp96 and the second
possibility is that GPM1 enhances the retrograde transport from
Golgi to ER, resulting in the decreased movement of gp96 to the
cell surface. Since surface expression of gp96 was abrogated in the
presence of brefeldin A (BFA), which leads to Golgi disturbance
and protein accumulation inside the ER [35], we monitored the
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translocation of gp96 from the Golgi to the cell surface by BFA
treatment. If GPM1 has an effect on endocytosis of cell surface
gp96, it should additionally suppress cell surface gp96 in the
presence of BFA. But, GPM1-induced suppression of surface gp96
was abrogated in the presence of BFA (Fig. 2C), suggesting that the
target point of GPM1 is the translocation of gp96 from the ER to
the cell surface. To determine the functional importance of
KDELR1 for the suppressive effect of GPM1 on the surface
localization of gp96, we introduced siRNA to knockdown
KDELR1 transcript and examined how GPM1 would affect the
surface levels of gp96. In the control cells, GPM1 reduced gp96
positive cell population (Fig. 2D). When the cells were transfected
with KDELR1 siRNA, GPM1 effect was ablated while gp96
positive cells were increased due to the depletion of KDELR1
(Fig. 2D). These results demonstrate that the suppressive effect of
GPM1 on the surface translocation of gp96 requires KDEL
receptor. We tested whether GPM1 would affect the binding of
Figure 1. Identification of gp96-binding compound that suppresses plasma membrane levels of gp96. (A) Heat map of primary
screening data. Inhibitory effects of 6,482 chemicals on the interaction of gp96 and AIMP1 were monitored by modified ELISA method as described.
Taking the value of DMSO as 0%, the inhibition of each chemical was indicated as relative percentage and the degree of the inhibition was
represented by a heat map in a 10% scale from 0 (green) to 100% (red). (B) Effect of the derivatives of the primary hits on surface expression of gp96.
RAW264.7 cells were treated with 77 compounds (10mM, 24h) and the effects on surface expression of gp96 were analyzed by flow cytometry. We
took 5% changes compared to the control group (15% of the gp96
+ cells) as cut-off values. Out of 77 compounds, 8 compounds showed suppressive
effect on surface expression of gp96 below 10% whereas 12 compounds showed increased gp96
+ cells more than 20%. The numbers indicate the
primary hits (see table S1) and the effects of their derivatives are shown as bar graphs. The compounds in the same plate are displayed as one color.
(C) Chemical structure of GPM1 and negative control (NC1) used in this study. (D) The dose-dependent effect of GPM1 or NC1 on the AIMP1-gp96
interaction using ELISA method as described. The indicated concentrations of the two compounds and biotin-conjugated murine gp96 were added
to AIMP1 coated on the surface of microtiter wells, and gp96 bound to AIMP1 was detected with strepavidin-conjugated peroxidase. (E) The binding
of GPM1 to gp96 was examined by surface plasmon resonance (SPR). GPM1 at the indicated concentrations was injected to immobilized gp96 and
the binding was measured using Biacore 3000. The response data were processed using data from a reference surface and buffer injections. Each
concentration was tested in triplicate. (F) Association rate constant (Ka), dissociation rate constant (Kd), and equilibrium dissociation constant (KD)
were determined for the interactions of GPM1 with various mutants of gp96 by the SPR experiments as described in Methods.
doi:10.1371/journal.pone.0009792.g001
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PLoS ONE | www.plosone.org 3 March 2010 | Volume 5 | Issue 3 | e9792Figure 2. The effect of the selected chemical on gp96 oligomerization and surface levels of gp96. (A) Splenocytes isolated from C57BL/6
mice were treated with vehicle (5% DMSO in PBS), GPM1, or NC1 (10mM, 24h), stained for cell surface gp96, and followed by flow cytometry. The
numbers indicate the percentage of gp96
+ splenocytes. (B) The effect of GPM1 on cell surface gp96, GRP78/Bip, PDI, and calreticulin. RAW264.7 cells
were treated with DMSO or GPM1 (10mM) for 24h. Cells were stained for cell surface gp96, GRP78/Bip, PDI, and calreticulin, followed by flow
cytometry. (C) RAW264.7 cells were treated with DMSO, GPM1 (10mM), or brefeldin A (1mg/ml) for 4h. Cells were stained for cell surface gp96, followed
by flow cytometry. (D) RAW264.7 cells were transfected with si-control or si-KDELR1 for 48h and then further treated with DMSO or GPM1 (10mM) for
24h. Cells were stained for cell surface gp96, and followed by flow cytometry. (E) RAW24.7 cells were treated with 10mM GPM1 for 24h. Cell lysates
were immunoprecipitated with control IgG or anti-gp96 antibody and the immunoprecipitated proteins were immunoblotted with anti-KDELR1, anti-
AIMP1 and gp96 antibodies. WCL means whole cell lysate. (F) RAW264.7 cells were treated with 10mM GPM1 for 24h. Cell lysates were fractionated
using sucrose density gradient. Proteins from ER fraction were immunoblotted with anti-gp96 antibody. Calnexin was used as an ER marker. (G) The
effect of GPM1 on gp96 oligomerization. 293 cells were transfected with RFP-tagged gp96 and His-tagged gp96. Cells were then treated with DMSO
or GPM1 (10mM) for 4h. Cell lysates were immunoprecipitated with anti-RFP antibody, and the precipitated proteins were immunoblotted using anti-
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between the two proteins. GPM1 increased the amount of gp96
bound to KDELR1 while blocking the binding of gp96 to AIMP1
(Fig. 2E left). However, GPM1 did not decrease the cellular levels
of three proteins (Fig. 2E right) and the ATPase activity of gp96
(Fig. S3A). The ER retention of gp96 is enhanced via its
interaction with AIMP1 that facilitates the oligomerization of
gp96 [32]. We thus examined whether GPM1 would functionally
mimic AIMP1 for the ER residency of gp96. When we isolated ER
fraction from control-treated or GPM1-treated cells, the ER
residency of gp96 was increased by GPM1 treatment (Fig. 2F).
The retrograde transport of gp96 from Golgi to ER is mediated
through the recognition of the C-terminal KDEL motif of gp96 by
the KDEL receptor [11]. Binding of gp96 to KDEL receptor leads
to its oligomerization [13] and retrieval to ER [14]. Thus,
oligomerization status of gp96 can be a signature for its ER
residency. Indeed, GPM1 treatment increased the amount of His-
tagged gp96 coimmunoprecipitated with RFP-tagged gp96
(Fig. 2G), suggesting that GPM1 can regulate gp96 oligomer
formation. When we monitored the conformational change of
gp96 induced by GPM1, the a-helicity of gp96 was slightly
increased as shown by circular dichroism spectroscopy (Fig. S3B).
Here we examined whether GPM1 would directly affect
oligomerization of gp96 using size exclusion chromatography.
When the purified gp96 was mixed with GPM1, the monomer
fraction of gp96 was shifted to the oligomers (Fig. 2H and I),
suggesting that the oligomerization of gp96 can be facilitated by
the binding to GPM1.
Based on these results, we propose the working mechanism of
GPM1 as schematically shown in Fig. 2J. Namely, gp96 can be
exposed to extracellular space upon various cellular stresses to trigger
autoimmune responses. GPM1 binds to the C-terminal dimerization
domain of gp96 and enhances oligomerization, leading to the KDEL
receptor-mediated retrograde transport to ER.
Suppression of Cell Surface gp96 by GPM1 Reduces DC
Maturation
In vivo effects of GPM1 were determined on cell surface
presentation of gp96 and DC maturation associated with SLE.
GPM1 was systemically delivered to gp96tm transgenic mice in
which the surface levels of gp96 are chronically enhanced [29]. We
used phosphate-buffered saline containing 5% DMSO and dexa-
methasone (Dex), an immunosuppressant of glucocorticoid family as
negative and positive control, respectively. Each group consisted of
age-matched nine female mice. During intraperitoneal administra-
tion for 2 months at the dose of 30mg/kg, GPM1-treated mice did
n o tg i v ea p p a r e n ta d v e r s ee f f e c t sw h e r e a st w oo ft h en i n eD e x - t r e a t e d
mice died during the treatment (Fig. 3A). After 2 month, we isolated
splenocytes from vehicle-, Dex-, and GPM1-treated mice and
determined the viability of splenocytes. GPM1 did not affect the
viability of splenocytes whereas Dex significantly damaged cell
viability (Fig. 3B). We then confirmed the effect of GPM1 on the
surface localization of gp96 of splenocytes from vehicle-, dexameth-
asone-, or GPM1-treated mice. We isolated MHC class II
+
splenocytes and lymph nodes from vehicle-, Dex-, and GPM1-
treated mice and determined the portion of gp96
+ cells by flow
cytometry. The percentages of gp96
+ MHC class II
+ cells in the
control, Dex- and GPM1-treated groups were about 57, 25 and 41%,
respectively, suggesting the suppressive effect of GPM1 on the surface
translocation of gp96 (Fig. 3C).
Gp96 has been implicated in the activation and maturation of DCs
via CD91 and Toll-like receptor (TLR) 2/4 [25]–[27]. Also, DCs
from gp96tm transgenic mice and AIMP1-deficient mice wereshown
to be hyperfunctional [29],[32]. We tested whether suppression of cell
surface gp96 through the increase of retrograde transport to ER
affected DC maturation in GPM1-treated mice. GPM1-treated mice
showed little difference in CD11b
+CD11c
+ myeloid DC and
CD11b
2CD11c
+ lymphoid DC populations (Fig. 3D upper). We
monitored the maturity of DCs by measuring the surface levels of
inducible costimulator ligand (ICOSL), one of the known DC
maturation markers using flow cytometry and found that GPM1
significantly reduced ICOSL levels in splenic CD11b
+CD11c
+
myeloid DC and splenic CD11b
+CD11c
2 macrophages (Fig. 3D
lower), and also reduced lymph node ICOSL
+CD11b
+CD11c
+
myeloid DCs (Fig. 3E). However, GMP1 gave little effect on the
ICOSL levels in CD11b
2CD11c
+ lymphoid DCs (Fig. 3E right
graph). The decreased expression of cell surface ICOSL correlates
with the decreased ability of GPM1-treated splenic DCs to activate
allogeneic naı ¨ve CD4
+ T cells, as measured by TNFa secretion
(Fig. 3F) and IFNc secretion (Fig. 3G). Based on these results, we
conclude that suppression of cell surface gp96 affected DC
maturation in GPM1-treated mice.
Suppression of Cell Surface gp96 by GPM1 Reduces B
Cells, Memory T cells in gp96tm Transgenic Mice
We then examined whether GPM1 could influence the cellular
phenotypes that can influence SLE-like phenotypes. The GPM1-
treated mice showed reduced populations of B220
+ and MHC
class II
+ cells in the spleen and in the lymph nodes (Fig. 4A and B
left two graphs, respectively). GPM1 gave little effect on the T cell
populations in both organs (Fig. 4A and B right three graphs). SLE
involves abnormal activation of CD4
+ T cells that accumulate as
activated memory cells and contributes to B cell activation and
expansion, and hypergammaglobulinemia [3],[4]. We found a
reduction in the population of CD4
+ memory cells and activated
CD4
+ T cells in the spleen and lymph nodes of GPM1-treated
mice (CD4
+CD44
high, CD4
+CD62L
low, and CD4
+CD69
+ cells;
Fig. 4C and D). GPM1 treatment also decreased mature B cell
population (B220
+IgM
+IgD
+; data not shown).
Suppression of Cell Surface gp96 by GPM1 Reduces
Renal Disease in gp96tm Transgenic Mice
We checked whether the typical SLE-like phenotypes are also
compromised by systemic administration of GPM1. Although
vehicle-treated mice displayed severe glomerulonephritis pheno-
types such as thickening of basement membrane and capillary
walls, vascular obliteration, increased mesangial cells, and renal
tubules packed with pink proteinaceous materials (Fig. 5A left
column and Table S2) and glomerular immunoglobulin deposition
(Fig. 5B top), GPM1 as well as Dex treatment alleviated the
His antibody. WCL, whole cell lysates. (H) FPLC gel filtration chromatography of gp96 protein. The purified gp96 (5mM) was incubated with DMSO or
GPM1 (50mM) for 1h on ice and then injected into a Superdex 200 10/300 GL size exclusion column. The positions of mass standards used for
calibration are indicated at the top of the chromatogram. Molecular weight: thyroglobin (670 kDa), ferritin (440kDa) and BAS (67kDa). Peak 1, 2, 3, and
4 indicate the position of oligomer, tetramer, dimer, and monomer of gp96 protein, respectively. (I) Peak fractions from gel filtration of DMSO or
GPM1-treated gp96 proteins were immunoblotted with anti-gp96 antibody. (J) Model for GPM1 action. In the absence of KDEL proteins such as gp96,
KDEL receptor exists mainly in monomeric form. GPM1 treatment leads to gp96 oligomerization and binding to KDEL receptor, which induces
retrograde transport of gp96 to ER. The data represent the means 6 S.D. Student t-test P values are shown.
doi:10.1371/journal.pone.0009792.g002
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PLoS ONE | www.plosone.org 5 March 2010 | Volume 5 | Issue 3 | e9792Figure 3. In vivo effect of the selected compound on DC maturation. (A) Survival rate of gp96tm transgenic female mice treated with vehicle
(n=9), GPM1 (n=9), and dexamethasone (n=9) at 30mg/kg/day. (B) The numbers of total splenocytes isolated from vehicle- (n=9), GPM1- (n=9),
and Dex (dexamethasone)- (n=7) treated mice. (C) Percentage of gp96
+ MHC class II
+ cell population in splenocytes from gp96tm transgenic female
mice treated with vehicle (control) (n=9), GPM1 (n=9), and dexamethasone (n=7) at 30mg/kg. (D) Cell surface ICOSL of CD11b
+CD11c
+ (myeloid
DCs), CD11b
2CD11c
+ (lymphoid DCs), and CD11b
+CD11c
2 (macrophages) cell populations in splenocytes from gp96tm transgenic female mice
treated with vehicle (n=9) and GPM1 (n=9) at 30mg/kg. (E) Cell surface ICOSL
+CD11b
+CD11c
2 cell populations in lymph nodes from gp96tm
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of kidney dysfunction, the serum levels of nuclear antigen-specific
and double stranded DNA-specific autoantibodies were also
reduced in GPM1-treated mice (Fig. 5C, D and E, respectively).
GPM1 treatment improved hypergammaglobulinemia symptom
shown in these mice [29] as determined by total serum levels of
IgG1, IgG2b, IgG3, IgM, and IgA (Fig. 5F).
These results show that the selective suppression of cell surface
gp96 in gp96tm transgenic mice reduced SLE disease severity. We
document possible one mechanism for this recovery, the reduction
of DC maturation. These results suggest that the surface gp96 is
critical cause of SLE-like disease and may be a useful target in the
treatment of SLE.
Discussion
SLE is a clinically heterogeneous autoimmune disorder with
diverse genetic causes [36], and the genes encoding HLA class II,
mannose binding protein (MBP), TNFa, the T cell receptor,
interleukin 6 (IL-6), CR1, immunoglobulin Gm and Km allotypes,
FcgRIIA and FcgRIIIA (both IgG Fc receptors), and heat shock
protein 70 are thought to be associated with SLE [37]. Despite the
complex molecular etiology of SLE, corticosteroids are commonly
used to treat most of the SLE patients but long term usage of these
drugs may induce numerous side effects, urging a need to develop
more target- or mechanism-based therapy with less adverse effect.
In this study, Dex showed several side effects on mouse and
splenocyte survival (Fig. 3A and B), and abdominal obesity (data
not shown) although Dex reduced phenotypes associated with
SLE. However, GPM1 did not show any effect on survival or
organ problems (data not shown) according to the long-term
treatment. At this moment, we do not yet know how much portion
of human SLE results from aberrant localization of gp96, and how
the effect of GPM1 is in other spontaneous lupus animal models.
These issues are currently under investigation.
The clinical need for novel targets and therapies for human
autoimmune disease is high. Previous reports have demonstrated
that several novel targets and drug-like compounds for autoim-
Figure 4. In vivo effect of the selected compound on various immune cells. (A) Percentage of B220
+,M H Cc l a s sI I
+,C D 4
+,C D 8
+,C D 4a n dC D 8
double negative cell populationsin splenocytes from gp96tm transgenic female mice treated withvehicle (n=9), GPM1(n=9), and dexamethasone (n=7)
at 30mg/kg. (B) Percentages of B220
+,M H Cc l a s sI I
+,C D 4
+,C D 8
+, CD4 and CD8 double negative cell populations in lymph nodes from gp96tm transgenic
female mice treated with vehicle (n=9), GPM1 (n=9), and dexamethasone (n=7) at 30mg/kg. (C) Percentage of CD4
+CD44
high (memory T cells),
CD4
+CD62L
low (effector T cells), and CD4
+CD69
+ (activated T cells) in splenocytes from gp96tm transgenic female mice treated with vehicle (n=9), GPM1
(n=9), and dexamethasone (n=7) at 30mg/kg. (D) Percentages of CD4
+CD44
high,C D 4
+CD62L
low, and CD4
+CD69
+ lymph node cells in vehicle- (n=9),
GPM1- (n=9), and dexamethasone- (n=7) treated mice. Student t-test P values comparing GPM1-treated mice with control are indicated.
doi:10.1371/journal.pone.0009792.g004
transgenic female mice treated with vehicle (n=9) and GPM1 (n=9) at 30mg/kg. Freshly isolated CD11c
+ splenic DCs from vehicle- or GPM1-treated
mice were tested for their abilities to stimulate allogeneic naı ¨ve WT CD4
+ T cells to produce TNFa (F) and IFNc (G). Student t-test P values are
indicated.
doi:10.1371/journal.pone.0009792.g003
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as a novel target for autoimmune disease via binding to Quinoline-
3-carboxamides [38]. Neubert et al. reported that proteosome
inhibitor bortezomib successfully depletes plasma cells and
protects mice from lupus [39]. Barber et al. reported that PI3Kc
inhibitor blocks SLE symptoms [40]. Johnson et al. reported that
mitochondrial F1F0-ATPase, which is a target of benzodiazepine
Bz-423, is a useful target for lupus [41]. In this study, we are
suggesting that cell surface gp96 is also candidate target for lupus.
GPM1 directly interacts with gp96 and hydrophobic residues
of gp96 within dimerization domain are important to GPM1
binding (Fig. 1E and F). Crystal structure of mammalian gp96
shows that along with the dimerization interface, helix C4 and
helix C5 of the C domain of gp96 contains GPM1 binding motifs
[18]. In the vicinity of helix C4 and C5, Helix C6 of the C-
terminal domain of gp96 forms disordered straps to give stability
to the gp96 dimer. In our result, since GPM1 confers slight
helical change of gp96 (Fig. S2C) and dimer/oligomer formation
of gp96 (Fig. 2G–I), we speculate that GPM1 stabilizes disordered
helix C6 straps of the C-terminal domain of gp96 to lead gp96
dimer formation.
SLE is characterized by abnormalities in dendritic cell (DCs),
autoreactive T cells and B cells [1],[2]. DCs are important in
regulating both immunity and tolerance and have been implicated
in the pathogenesis of SLE [1]. DCs induce naı ¨ve T cell activation
and stimulate B cell growth and differentiation. The lupus-
associated DCs producing altered signals amplify autoreactive
specificities in T cells, which, in turn, stimulate autoreactive B
cells, leading to the increase of autoantibodies. Since cell surface
gp96 induced significant DC activations [29],[32], we employed a
chemical method to intervene over-maturation of DCs via gp96.
The results of this work consistently show that aberrant surface
exposure of gp96 can be chemically controlled. The selective
suppression of cell surface gp96 reduced the incidence and severity
of SLE-associated phenotypes, suggesting gp96 as a potential
target to control autoimmune disease like SLE.
Figure 5. In vivo effect of the selected compound on SLE-associated phenotypes in gp96tm transgenic mice. (A) Representative kidney
sections stained with hematoxylin and eosin from control (n=9), GPM1- (n=9) and dexamethasone (Dex)-treated (n=7) groups. (B) Glomerular
immunoglobulin deposition is shown by green fluorescence with FITC-conjugated goat anti-mouse Ig antibody in vehicle and GPM1-treated kidney.
(C) Protein concentrations (mg/ml) in the urines, serum levels of nuclear antigen-specific (D) and double strand DNA-specific antibody (E) were
compared between control (n=9), GPM1- (n=9) and dexamethasone (Dex)-treated (n=7) groups. Arbitrary units represent autoantibody absorbance
at OD450nm at 1: 101 serum dilution. (F) Serum Ig levels from control (n=9), GPM1- (n=9), and Dex-treated (n=7) groups by ELISA. Total IgG1, IgG2a,
IgG2b, IgG3, IgM, and IgA levels were determined using sandwich ELISA kits from Southern Biotechnology Associates (Birmingham, AL). Data
represent the mean6S.D. Student t-test P values comparing GPM1-treated mice with control are shown.
doi:10.1371/journal.pone.0009792.g005
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Drug Administration
Female gp96tm transgenic mice were bred and maintained at
the animal center for pharmaceutical research, Seoul National
University. We used age-matched, 12,26 weeks old mice in each
experimental group. To suppress cell surface gp96 we used GPM1
compound. Dexamethasone and GPM1 were dissolved in 5%
DMSO in phosphate-buffered saline (PBS) and control vehicle was
5% DMSO in PBS. Compounds were administered i.p. every 24h
for 2 months (30mg/kg/day). Three groups of each 9 mice were
examined. All procedures were conducted in accordance with the
Guide for the Care and Use of Laboratory Animals, published by the
Korean National Institute of Health. This study was approved by
Review Board of Institute of Laboratory Animal Resources of
Seoul National University.
Flow Cytometry
Spleen and lymph node cell suspensions were prepared by
grinding tissue through sterile mesh and erythrocytes were lysed
with RBC lysis buffer (eBioscience, CA). For surface staining,
antibodies were fluoresceinisothiocyanate (FITC)-, phycoerythrin
(PE)-, PerCP-, or APC-conjugated. Antibodies used were CD4
(RM4-5, H129.12), CD8 (53-6,7), B220 (RA3-6B2), CD11b (M1/
70), CD11c (HL3), CD44 (IM7), CD62L (MEL-14), CD69
(H1.2F3), CD25 (PC61.5), IgM (11/41), IgD (11-26C.2a),
calreticulin (BD Pharmingen, CA), MHC class II (M5/114.15.2),
Foxp3 (FJK-16s) (eBioscience, CA), gp96(Santacruz, CA), and PDI
(Assay Designs, MI). After staining, cells were washed and
analyzed on a FACScan flow cytometer using CellQuest software
(BD Bioscience, Mountain View, CA).
Mixed Lymphocyte Reaction
Splenic DCs (8610
3) from vehicle- or GPM1-treated mice were
purified using CD11c magnetic beads (Miltenyi Biotec, Auburn,
CA), fixed with 1% paraformaldehyde, and co-cultured with
1.5610
5 purified allogeneic CD4
+ T cells. Culture supernatants
were collected for TNFa assay using ELISA kit from Pierce
Biotechnology Inc. (Rockford, IL).
ELISA Assay for Chemical Screening
96-well plates (Maxisorp., F96; Nunc) were coated with 500ng/
well AIMP1in PBS (pH 7.4). After washing, the remaining sites
were blocked with PBS containing 1% BSA for 1h. Binding of
10ng/well biotin-conjugated gp96 was performed in Tris buffer
(25 mM Tris, 10 mM NaCl and 0.4% Triton X-100). Each of the
6,580 compounds was added to the well at 100nM and the plates
were washed and incubated with HRP-conjugated streptavidin in
PBS containing 0.1% BSA and 0.1% Tween 20 for 30 min. The
plates were washed, and then substrate was added to each well.
The absorbance was monitored at 450 nm.
Histology
Kidney tissue sections of gp96tm transgenic mice were fixed in
10% formaldehyde in PBS and dehydrated using an alcohol
gradient. After paraffin infiltration, the tissues were sectioned using
a microtome, stained with hematoxylin and eosin (H&E) and
analyzed by light microscopy. For immunofluorescent staining,
kidneys were sectioned with a cryostat. These cryosections were
blocked with normal goat serum, stained with FITC-conjugated
goat anti-mouse Ig (BD pharmingen, CA), and then observed by
fluorescent microscopy. Glomerulonephitis was quantitated ac-
cording to Berden scores [42].
Surface Plasmon Resonance (SPR)
Human gp96 was expressed as His tag fusion protein in
Escherichia coli BL21 (DE3) and purified by nickel affinity
chromatography. His-tagged human gp96 was immobilized onto
CM5 sensor chips using standard amine coupling
2. PBS was used
as a running buffer. The carboxymethyl dextran surface within
one side of the flow cell was activated with a 7-min injection of a
1:1 ratio of 0.4M EDC and 0.1M NHS. The protein was coupled
to the surface with a 7-min injection of gp96 diluted in 10mM
sodium acetate, pH 3.7. Remaining activated groups were blocked
with a 7-min injection of 1.0M ethanolamine, pH 8.5. GPM1
compound was dissolved directly in the PBS running buffer
containing 1% DMSO and injected at a flow rate of 20ml/min at
25uC and the binding was determined by the change in resonance
units (RU). The compound concentration varied from 10nM to
25mM and each concentration was tested at least three times. All of
the bound complexes dissociated back to baseline within a
reasonable time frame; therefore, no regeneration was required.
Sensorgram was processed by subtracting the binding response
recorded from the control surface, followed by subtracting an
average of the buffer blank injections from the reaction spot
3.T o
determine kinetic rate constants, all data sets were fit to a simple
1:1 binding with drifting baseline model using BIAevaluation
program.
Purification of gp96
His-tagged gp96 protein was expressed in E. coli BL21 (DE3)
and purified by nickel affinity chromatography and by gel
filtration chromatography, and dialyzed against buffer (25mM
Tris-HCl, pH7.5, 50 mM NaCl).
Circular dichroism (CD)
The gp96-GPM1 complex was prepared at a molar ratio 1:10
(5mM:50mM) in 250ml of buffer (25mM Tris-HCl, pH7.5, 50mM
NaCl). The final concentration of DMSO was 0.1%. The complex
was incubated at 20uC for 1h before CD measurements were
taken. Samples were loaded in a 0.2 cm CD cell, and the spectra
were acquired at 20uC using Jasco J-810. Wavelength scans were
performed between 195 and 260 nm. The signal was digitized at
1nm intervals and each final scan was an average of 3 repeats and
is presented after baseline buffer correction.
FPLC of gp96
FPLC gel filtration was used to separate gp96 monomer, dimer,
and oligomer. gp96 or gp96-GPM1 complex containing a 1:10
molar ratio of gp96 to GPM1 were injected into a Superdex 200
10/300 GL (GE healthcare, 10 mm i.d. 630 cm length) size
exclusion column. The elution (0.5 ml/min) was carried out with
buffer (20mM KH2PO4, 500mM NaCl, pH7.8, 2mM b-
mercaptoethanol, 300mM imidazole). Fractions of a volumn of
0.5 ml were collected during 60 min.
Statistical analysis
The student’s t-test was used for statistical analysis. P values of
,0.05 were considered to represent statistically significant
differences.
Supporting Information
Figure S1 The binding of GPM1 to protein disulfide isomerase
(PDI) (A) and GRP78/Bip (B) were examined by surface plasmon
resonance (SPR). GPM1 at the indicated concentrations was
injected to immobilized PDI and GRP78/Bip, and the binding
was measured using Biacore 3000. The response data were
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injections. Equilibrium dissociation constant (KD) was determined
for the interaction of GPM1 with PDI and GRP78/Bip.
Found at: doi:10.1371/journal.pone.0009792.s001 (0.28 MB TIF)
Figure S2 The effect of point mutations on the ATPase activity
of gp96. The effect of gp96 point mutations on its ATPase activity
was examined using ATPase assay kit (Innova Biosciences,
Cambridge, UK). One unit is the amount of enzyme that catalyzes
the reaction of 1mmol substrate per minute. The enzymatic activity
was calculated according to manufacturer’s instruction.
Found at: doi:10.1371/journal.pone.0009792.s002 (0.10 MB TIF)
Figure S3 The effect of GPM1 on gp96 ATPase activity and
conformational change. (A) The dose-dependent effect of GPM1
on the ATPase activity of gp96. The gp96 activity in the absence
of GPM1 was 0.0206660.00334 unit/ml and GPM1 showed little
effect on the ATPase activity within the range of the tested
concentration (0 vs. 100mM, p=0.071). (B) Circular dichroism
spectrum of free and GPM1-bound gp96 protein. GPM1 (50mM,
.95% purity) was mixed with gp96 (5mM). The CD spectra were
normalized by buffer containing 0.1% DMSO.
Found at: doi:10.1371/journal.pone.0009792.s003 (0.16 MB TIF)
Table S1 Summary of the screening of the chemicals derived
from the primary hits that inhibit the interaction between gp96
and AIMP1 more than 95% of the control at 0.1mM.
Found at: doi:10.1371/journal.pone.0009792.s004 (0.19 MB TIF)
Table S2 Comparison of glomerulonephritis in gp96tm trans-
genic mice treated with vehicle (n=9), GPM1 (n=9), or
dexamethasone (n=7). Glomerulonephitis was quantitated ac-
cording to Berden scores
26.
Found at: doi:10.1371/journal.pone.0009792.s005 (0.14 MB TIF)
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